Device
tSMS
tSMS is a medical device with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DEVICE
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
2
50%
Ph not_applicable
2
50%
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
N/ANon-phased studies
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Other(2)
Detailed Status
Completed2
unknown2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 22 (50.0%)
N/A2 (50.0%)
Trials by Status
completed250%
unknown250%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
tSMS in Essential Tremor
NCT03780426
unknownnot_applicable
Manual Dexterity Modifications After Application of tSMS Over the Primary Motor Cortex (M1)
NCT05260190
unknownnot_applicable
Transcranial Static Magnetic Field Stimulation (tSMS) in Amyotrophic Lateral Sclerosis (ALS).
NCT04393467
completedphase_2
Prevention of Levodopa-induced Dyskinesias by Transcranial Static Magnetic Field Stimulation (tSMS)
NCT02657681
Clinical Trials (4)
Showing 4 of 4 trials
NCT03780426Phase 2
tSMS in Essential Tremor
NCT05260190Not Applicable
Manual Dexterity Modifications After Application of tSMS Over the Primary Motor Cortex (M1)
NCT04393467Not Applicable
Transcranial Static Magnetic Field Stimulation (tSMS) in Amyotrophic Lateral Sclerosis (ALS).
NCT02657681Phase 2
Prevention of Levodopa-induced Dyskinesias by Transcranial Static Magnetic Field Stimulation (tSMS)
All 4 trials loaded
Drug Details
- Intervention Type
- DEVICE
- Total Trials
- 4